A tiny Long Island biotechnology startup in a global race to develop a COVID-19 vaccine has rolled out plans for a human trial. The Phase 1 trial using about 50 paid young adult volunteers will evaluate the ...

Open Orphan's Cathal Friel discusses their new contract with a top 3 pharma company in this exclusive interview with DirectorsTalk.

Pharmaceutical services company, Open Orphan has signed a new contract, valued at €4.4m, with a global pharmaceutical company to  provide a respiratory syncytial virus (RSV) human challenge study trial. The Dublin-listed ...

Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, has ...

Dublin-listed pharmaceutical services company Open Orphan has signed a new contract with a Japanese group which it expects will generate “significant revenue” for subsidiary Venn Life Sciences over the next year. Open ...

Dublin-listed Open Orphan has won a contract to conduct a trial into a vaccine for Covid-19. The deal is with Codagenix and 48 adults will volunteer for the clinical trial. ...

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, has ...

Dublin-listed pharmaceutical services company Open Orphan has signed a new deal with New York-based Codagenix for the phase one trial of a new Covid-19 vaccine. The trial, which will evaluate the safety and ability ...

Dublin-listed pharmaceutical company Open Orphan has announced a new contract with Codagenix to conduct a first human trial evaluating safety and immunogenicity of a single-dose Covid-19 vaccine. hVIVO, part of ...

Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, has ...